Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-04

Clinical Trial Update: Obinutuzumab in Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

This update reports an ongoing Phase 2 clinical trial of obinutuzumab for marginal zone lymphoma, currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gazyva (Obinutuzumab)

Snippet

Sponsor: Christian Buske | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING